Alnylam Pharmaceuticals
ALNY
#878
Rank
โ‚น2.753 T
Marketcap
โ‚น20,578
Share price
-1.48%
Change (1 day)
-45.93%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): โ‚น346.28

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น361.15. In 2025 the company made an earnings per share (EPS) of โ‚น171.52.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น346.28101.89%
2025โ‚น171.52
2023-โ‚น336.37-62%
2022-โ‚น885.2429.03%
2021-โ‚น686.09-3.36%
2020-โ‚น709.91-8.48%
2019-โ‚น775.667.67%
2018-โ‚น720.3939.74%
2017-โ‚น515.5212.94%
2016-โ‚น456.4438.84%
2015-โ‚น328.75-32.88%
2014-โ‚น489.79259.44%
2013-โ‚น136.26-31.25%
2012-โ‚น198.20

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
โ‚น668.94 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น243.91-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น4,053 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น54.32-115.04%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น69.56-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น25.73-107.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น130.55-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น77.18-78.63%๐Ÿ‡บ๐Ÿ‡ธ USA